Search Within

Advanced Practice Providers

  1. "Gastrointestinal Oncology Service"
Formats
  1. Meeting Abstract (72)
  2. Journal Article (59)
  3. Research Letter (2)
  4. Book Section (1)
  5. Editorial (1)
  6. Miscellaneous (1)
  7. Review (1)
Groups
  1. Department of Medicine (137)
  2. Gastrointestinal Oncology Service (137)
  3. Solid Tumor Oncology Division (137)
  4. Nursing (115)
  5. Center for Pancreatic Cancer Research (62)
  6. Survivorship Research (55)

More Groups

People
  1. Ellen Hollywood (37)
  2. Leonard Saltz (31)
  3. Armin Shahrokni (30)
  4. Diane Reidy (28)
  5. Andrew Epstein (27)
  6. Beatriz Korc-Grodzicki (26)

More People

Years
  1. 2025 (4)
  2. 2024 (4)
  3. 2023 (6)
  4. 2022 (9)
  5. 2021 (14)
  6. 2020 (13)

More Years

Publications
  1. Journal of Clinical Oncology (56)
  2. Journal of Pain and Symptom Management (8)
  3. JCO Oncology Practice (7)
  4. Journal of the American Geriatrics Society (5)
  5. Annals of Oncology (4)
  6. Cancer (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. Elsevier Inc. (15)
  3. Wiley Blackwell (11)
  4. Oxford University Press (7)
  5. American Association for Cancer Research (5)
  6. Springer (4)

More Publishers

Results (137)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Simplification of bevacizumab (bev) administration: Do we need 90, 60, or even 30 minute infusion times?
    Meeting Abstract

    Saltz, L. B.; Chung, K. Y.; Timoney, J.; Park, V.; Hollywood, E.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer
    Meeting Abstract

    Chung, K. Y.; Minsky, B.; Schrag, D.; O'reilly, E.; D'adamo, D.; Hollywood, E.; Quinones, M.; Saltz, L.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
    Meeting Abstract

    Saltz, L. B.; Lenz, H. J.; Hochster, H.; Wadler, S.; Hoff, P.; Kemeny, N.; Hollywood, E.; Gonen, M.; Wetherbee, S.; Chen, H.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Phase I and pharmacokinetic trial of a novel inhibitor of NAD biosynthesis in patients with solid tumors
    Meeting Abstract

    Holen, K. D.; Bolling, C.; Saltz, L. B.; Graefe, T.; Ty, V.; Sogo, N.; Starkmann, H.; Burk, K. H.; Hollywood, E.; Hanauske, A. R.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
    Journal Article

    Zhu, Y.; Sharma, S.; Saltz, L. B.; Kemeny, N.; Kelsen, D. P.; Ilson, D.; O'reilly, E.; Zaknoen, S.; Baum, C.; Statkevich, P.; more...
    Annals of Oncology (2002)

    Fulltext@MSK | Save
  • Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks
    Journal Article

    Sharma, S.; Kemeny, N.; Schwartz, G. K.; Kelsen, D.; O'reilly, E.; Ilson, D.; Coyle, J.; De Jager, R. L.; Ducharme, M. P.; Kleban, S.; more...
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • Interferon alpha‐2a and 5‐fluorouracil for advanced colorectal carcinoma: Assessment of activity and toxicity
    Journal Article

    Kemeny, N.; Younes, A.; Seiter, K.; Kelsen, D.; Sammarco, P.; Adams, L.; Derby, S.; Murray, P.; Houston, C.
    Cancer (1990)

    Fulltext@MSK | Save